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ABSTRACT 
Treatment of infectious posterior uveitis represents a therapeutic challenge for ophthalmologists. The eye is a privileged 
site, maintained by blood ocular barriers, which limits penetration of systemic antimicrobials into the posterior segment. 
In addition, topical and subconjunctival therapies are incapable of producing sufficient drug concentrations, 
intraocularly. Posterior infectious uveitis can be caused by bacteria, virus, fungi, or protozoa. Mode of treatment varies 
greatly based on the infectious etiology. Certain drugs have advantages over others in the treatment of infectious uveitis. 
Topical and systemic therapies are often employed in the treatment of ocular infection, yet the route of treatment can 
have limitations based on penetration, concentration, and duration. The introduction of intravitreal antimicrobial 
therapy has advanced the management of intraocular infections. Being able to bypass blood-ocular barriers allows high 
drug concentrations to be delivered directly to the posterior segment with minimal systemic absorption. However, 
because the difference between the therapeutic and the toxic doses of some antimicrobial drugs falls within a narrow 
concentration range, intravitreal therapy could be associated with ocular toxicity risks.  In many cases of infectious 
uveitis, combination of intravitreal and systemic therapies are necessary. In this comprehensive review, the authors 
aimed at reviewing clinically relevant data regarding intraocular and systemic antimicrobial therapy for posterior 
segment infectious uveitis. The review also discussed the evolving trends in intraocular treatment, and elaborated on 
antibiotic pharmacokinetics and pharmacodynamics, efficacy, and adverse effects. 
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ANTIMICROBIAL THERAPY FOR INFECTIOUS UVEITIS 
INTRODUCTION
Infectious posterior uveitis is an uncommon type of 
uveitis. It can occur after ocular surgery or trauma, as a 
consequence of systemic infection, or due to activation 
of latent infection. Because posterior segment infectious 
uveitis is a sight threatening disease, early recognition 
with prompt treatment is fundamental to prevent severe 
loss of vision [1]. The success of treating infections with 
antimicrobial therapy depends on the characteristics of 
the particular pathogen, e.g. the virulence of the 
organisms and the rate of regrowth of persistent 
organisms, as well as host- and drug-related factors, 
including the initial load, pharmacokinetic and dynamic 
characteristics of the antimicrobial agent, and the host 
immune mechanisms [2]. 
Despite advances in diagnostic techniques and the 
introduction of new antimicrobial drugs, treatment of 
infectious uveitis remains a therapeutic challenge. The 
eye is a privileged site, maintained by blood ocular 
barriers, which limits penetration of systemic 
medications to the posterior segment. Over the past two 
decades, intravitreal drugs have revolutionized the 
outcomes of vitreoretinal diseases, including uveitis. 
Advantages of  intravitreal therapy in infectious uveitis 
include circumvention of  blood-ocular barriers with 
direct delivery of antimicrobial drugs  as well as 
decreased systemic drug absorption [3]. 
Blood-ocular Barriers 
The blood ocular barrier separates the ocular tissue from 
blood circulation, responsible for active and passive 
exchange between circulation and intraocular structures. 
It is divided to the blood-retinal barrier and the blood-
aqueous barrier. In a normal physiologic state, the eye is 
poorly penetrated by systemic drugs; and thereby, 
achievement of high intraocular concentration is 
hindered. However, blood ocular barriers can be 
penetrated with ideal tissue pH, molecular weight, 
lipophilicity, and ionization with variable degree [4]. The 
blood-aqueous barrier is located at the endothelium of 
the iris vessels and the non-pigmented ciliary body 
epithelium, in which tight junctions form the main sites 
of resistance for drug diffusion to the aqueous humor. 
The pigmented epithelium and non-pigmented 
epithelium of the ciliary body are divided by tight 
junctions, composed of proteins, such as claudin-1, 
occludin, and ZO-1 [5, 6]. The blood-ocular barrier can be 
broken down or bypassed in certain non-physiological 
states, including intraocular inflammation and following 
surgical procedures [7].  
The blood-retinal barrier is further divided to the outer 
and inner blood retinal barrier. The outer blood-retinal 
barrier, composed of tight junctions and adjacent 
adherens junctions, separates the sub-retinal space from 
the choroidal circulation. The inner blood-retinal barrier 
is analogous to the blood-brain barrier and formed by 
tight junctions of the endothelial cells of retinal blood 
vessels [4, 8].
 
The blood-retinal barrier is compromised 
by a variety of insults, such as chemical, thermal, or 
traumatic injury to the retinal vessels. The degree of 
leakage can be quantified using vitreous fluorometery 
and more accurately mapped by the Retinal Leakage 
Analyzer, a modified confocal laser ophthalmoscope 
scanning technique [9]. In contrast to the retinal 
vasculature, the blood supply to the choroid is enormous 
with large fenestrations of 20 to 40 micrometer (μm) in 
the choriocapillaris, allowing diffusion of molecules at 
high concentration to the choroidal tissue and the sub-
retinal space [10]. 
To obtain therapeutic drug concentrations in the vitreous 
and the retina requires either systemic or intravitreal 
drug administration as opposed to subconjunctival or 
sub-Tenon route, which are unable to reach sufficient 
concentrations. High doses of systemic medications are 
needed to achieve adequate concentrations in the 
vitreous, due to limited blood flow and the blood–retinal 
barriers. Moreover, systemic absorption of drugs may 
lead to undesirable adverse events. However, because of 
the anatomical characteristics of the choroidal 
circulation, systemic medications reach the choroid at 
high concentrations, thus, infections, mainly confined to 
the choroid/outer retina, such as TB choroiditis and early 
fungal chorioretinitis, can be adequately managed with 
systemic antimicrobials alone [10]. 
Compared to the systemic route, intraocular injections of 
antimicrobial drugs to the vitreous cavity allows rapid 
delivery of very high drug concentrations to the posterior 
segment, as it bypasses blood–retinal barriers. This is of 
significant benefit in patients, who have sight threatening 
infections involving zone 1 (defined as 3000 μm from the 
fovea or 1500 μm from the optic nerve head) of the 
retina [11]. As the concentrations of antimicrobial drugs 
in the vitreous, achieved after intravitreal injection, 
significantly exceeds the Minimum Inhibitory 
Concentration (MIC) for common organisms (Super-MIC), 
the majority of antibiotics are likely to be bactericidal at 
these concentrations. Because bacterial kill rate is a 
function of drug concentration and contact time, it is 
possible that intravitreal antibiotics may also have an 
effect for longer than expected, even as their 
concentration decreases. Additionally, bacteria may 
create biofilms around intraocular lens implants that 
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make them less susceptible to antibiotics [12]. Very high 
drug concentration is needed to inhibit bacterial growth 
within these biofilms, and this could only be achieved via 
intravitreal drug administration. 
Intraocular therapy also offers the opportunity to avoid 
adverse effects of systemic medications, which is of 
particular significance in pregnant or systemically ill 
patients. However, intraocular drug administration has 
several caveats. Since the adequate therapeutic level of 
most drugs usually falls in a narrow concentration range, 
decreasing ocular toxicity requires explicit control of drug 
concentration and injection volume. Also, intravitreal 
treatment does not provide treatment for the fellow eye 
or for any associated systemic infection, thus, it may not 
be sufficient alone in certain types of infectious uveitis. 
Other drawbacks include a small risk of injury to the 
crystalline lens or retina during the injection, as well as 
the risk of endophthalmitis [13].  
Pharmacokinetics of Intraocular Therapy 
Various models have been designed to study the 
pharmacokinetics of intravitreal injection [14, 15].
 
Tojo 
and Isowaki designed a model, which assumed a 
cylindrical vitreous body in contact with a 
retinal/choroidal/scleral membrane on one side and the 
posterior capsule and aqueous humour on the other. This 
model suggested that drug molecules first diffuse 
through the vitreous and then move to surrounding 
tissues. The drug molecules are mainly released from the 
vitreous, through the aqueous humour. Secondarily, drug 
elimination takes place posteriorly by active and passive 
transport across the blood-retinal barrier. In general, 
drugs that are eliminated through the aqueous humour 
route, have longer half-life than those cleared from the 
vitreous via the posterior route [16]. Large molecules and 
cationic drugs (e.g. aminoglycosides and vancomycin) are 
primarily cleared through the anterior route while small 
molecules and anionic drugs (e.g. cephalosporins and 
clindamycin) are eliminated via the posterior route. In 
addition to the physical properties of drugs, ocular 
inflammation and previous ocular surgery (i.e. cataract 
removal, vitrectomy) can also influence the half-life of 
drugs in the vitreous. In inflammation, active transport 
through the blood-retinal barrier is decreased, causing 
decreased elimination of drug [17], while elimination 
through the anterior route through the aqueous is 
increased [18]. In aphakia, clearance of drugs that are 
mainly eliminated through the aqueous are enhanced, 
while vitrectomy surgery results in rapid clearance of 
antimicrobial drugs that depend on the posterior route 
[19, 20]. Notably, however, the use of vitreous 
tamponade in vitrectomised eyes may delay the 
elimination of intravitreal antibiotics from the vitreous 
cavity, and reduction of intravitreal antibiotics doses in 
silicone-filled eyes has been recommended to decrease 
the risk of retinal toxicity [21]. 
Pharmacodynamics of Antimicrobial Drugs 
Antibiotics are divided to two main classes, according to 
their antibacterial activity, and bacteriostatic and 
bactericidal properties. Bacteriostatic drugs (e.g. 
clindamycin, and trimethoprim/sulfamethoxazole) 
function by inhibiting the growth or replication of 
bacteria. This, however, does not result in bacterial 
death, and, therefore, elimination of the bacteria 
requires assistance from the host immune system. In 
contrast, bactericidal drugs (e.g. cephalosporins, 
vancomycin, gentamycin, amikacin, and moxifloxacin) 
induce bacterial killing. A clear distinction between these 
two classes is not always possible, for instance, 
bacteriostatic drugs may induce bacterial killing, if used 
at high concentrations [2].  
The minimum inhibitory concentration (MIC) of an 
antibacterial agent is defined as the lowest 
concentration, at which it suppresses the growth of 10
5
 
colony forming units of bacteria/mL, after adequate 
incubation [22]. Minimum bactericidal concentration 
(MBC) is considered as the gold standard for evaluating 
susceptibility of microorganisms to antimicrobial agents 
and is used to determine the potency of antimicrobial 
agents. The minimum drug concentration, which 
decreases ≥99.9% of the viability of the bacteria, is 
known as MBC. For bactericidal drugs, the MBC is usually 
not more than four folds greater than the MIC, and drug 
concentrations of proven clinical efficacy are about 10 
folds higher than the MIC for most bacteria [2].  
Bactericidal drugs can be further subdivided, according to 
their killing mechanism to two groups. First are 
concentration-dependent bactericidal drugs (e.g. 
aminoglycosides), in which the rate and extent of 
bacterial killing are directly related to the concentration 
of the drug. Thus, the dosing strategy should aim at 
achieving levels that are much higher than MBC. The 
second group is the time-dependent bactericidal drugs 
(e.g. vancomycin and cephalosporins), where efficacy is 
mainly dependent on the time, at which exposure is 
maintained above the MBC and, thus, progressive 
escalation of drug concentrations would not further 
enhance the bactericidal activity [23]. 
Use of the Suprachoroidal Space 
Utilization of the Suprachoroidal Space (SCS) has been a 
topic of recent interest in its ability to locally treat 
intraocular disease [24]. Suprachoroidal injection has 
been postulated as a potential treatment for posterior 
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uveitis, macular edema, glaucoma, Age-related Macular 
Degeneration (AMD), stem cell therapy, and retinal 
prostheses [24]. Access to the SCS has been 
accomplished by cannulation and hypodermic needle, yet 
recent microneedle delivery at the limbus is of particular 
interest due to easier access and enhanced safety. In an 
experiment accessing the SCS of mouse eyes, molecules 
and particles were shown to have targeted the 
chorioretinal region from seconds to months, depending 
on the size of the substances. Eluting drugs could 
possibly be used due to the sieve-like elimination of drug 
particles [24]. Molecular clearance from the SCS tends to 
be eliminated via three pathways. Within 10 minutes, 
fluid and molecules exit by diffusion into the sclera and 
choroid, and pressure-driven movement through trans-
scleral leakage sites. Within one hour, molecules exit 
through the choroidal vasculature. Finally, between one 
and ten hours, molecules exit through the scleral, 
secondary to diffusion and convection [24]. Chen et al. 
[25] showed that in mice eyes, aqueous humor, peak 
concentrations in the posterior portion of the vitreous, 
and retina were 0.69 nanogram/milliliter (ng/mL), 1 912 
ng/mL and 400 369 ng/mL, respectively, after 50 
microliter (µL) of triamcinolone acetate suprachoroidal 
injection. Ocular distribution studies in rabbits showed a 
10-fold higher concentration of triamcinolone in the 
posterior segment after SCS injection when compared to 
intravitreal injection, and a 10-fold increase in 
chorioretinal selectivity after six hours, defined as 
concentration in the chorioretinal tissues compared to 
concentration in the lens [26]. Although accessing the 
SCS does not involve complete penetration of the globe, 
complications include suprachoroidal hemorrhage and 
increased intraocular pressure [24]. 
Antibacterial Therapy 
Rationale for Treatment 
Bacterial endophthalmitis may occur after intraocular 
surgical procedures (postoperative), following 
penetrating trauma (post-traumatic) or as a result of 
haematological spread from a distant site of infection 
(endogenous).
 
The majority of cases of bacterial 
endophthalmitis are encountered after cataract surgery 
and intravitreal injections. 
While intravitreal therapy is the main stay for 
posttraumatic and postoperative infection, the rational 
of treatment in endogenous endophthalmitis is based on 
treatment with both systemic antibiotics to treat the 
source of infection, as well as intravitreal therapy, to 
treat the intraocular infection [27]. Choice of systemic 
antibiotic is mainly guided by the nature of systemic 
infection with preference given to medications that have 
good penetration in the posterior segment. There is data 
to suggest that quinolones, particularly moxifloxacin, that 
have better intraocular penetration, may have a 
beneficial impact on visual outcome [28, 29]. The role of 
Pars Plana Vitrectomy (PPV) in endogenous 
endophthalmitis is not clearly defined yet there appears 
to be a trend towards early PPV. Early vitrectomy in 
endogenous endophthalmitis secondary to Klebsiella 
pneumoniae was shown to improve visual acuity to HM 
or better, in 50% of eyes, while preserving all eyes 
anatomically in the study [30]. A randomized study of 
108 eyes with endogenous endophthalmitis showed that 
eyes with vitrectomy plus Silicone Oil (SO) tamponade 
were more likely to have successful outcomes, defined as 
vision of counting fingers at one meter or better and less 
risk of  retinal detachment: Eyes with SO tamponade 
achieved success in 63.7% of cases compared to 43.4% in 
eyes solely with PPV [31]. 
Intravitreal Vancomycin 
Mechanism of Action and Pharmacokinetics 
Vancomycin is a bactericidal agent that causes cell lysis 
through prevention of the polymerization of 
peptidoglycan in the cell. Ferencz et al. reported that 
therapeutic vitreous vancomycin concentrations were 
only achieved with intravitreal treatment and not 
intravenous administration for the treatment of gram-
positive endophthalmitis [32]. Though some physicians 
use a dose of two milligrams (mg), the commonly used 
intravitreal dose of vancomycin is 1 mg, as recommended 
by the endophthalmitis Vitrectomy Study (EVS) [33]. This 
dosage results in vitreous concentration that is 
significantly higher (50 to 200-fold) than MIC of most 
gram positive organisms. Vancomycin has a half-life in 
the vitreous, from 25 to 56 hours, as demonstrated in 
infected rabbit eyes, with drug concentration being 
maintained above bactericidal level for up to 72 hours 
[34, 35]. As the antibacterial activity of vancomycin is 
mainly time-dependent rather than concentration-
dependent, some authors recommend an alternative 
smaller dose regimen of 0.2 mg with repeat injection 
using the same dose after three to four days [36].
 
Spectrum of Activity And Resistance 
Vancomycin has been the antibiotic of choice for 
coverage of gram-positive organisms, given the increased 
incidence of β-lactam antibiotic resistance. Vancomycin 
achieves nearly 100% efficacy for the treatment of gram-
positive endophthalmitis (including methicillin-resistant 
Staphylococcus species), yet it does not have any 
significant activity against gram-negative organisms [37]. 
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Vancomycin resistance is rare, however, it is seen in 
some cases with Bacillus and Enterococcus species [38].
 
 
Adverse Effects 
Vancomycin is reported to be safe in doses up to 2 mg in 
rabbit eyes [39]. Mochizuki et al. found that a dose of 1.0 
mg of vancomycin caused no electroretinographic 
changes for at least eight weeks after injection in rabbit 
eyes. However, with a higher dose of 10 mg, the 
Electroretinogram (ERG) was non-recordable with only 
partial recovery afterwards [40]. Intracameral 
vancomycin is controversial, given its historical 
association with postoperative macular edema. Axer-
Siegel et al. reported, in a randomized controlled trial, a 
2.8-fold risk of cystoid macular edema after using 
intracameral vancomycin during extracapsular cataract 
extraction, as prophylaxis against postoperative 
endophthalmitis [5]. However, more recent Optical 
Coherence Tomography (OCT)-based studies showed no 
difference in retinal thickness after intracameral 
vancomycin as compared to either no antibiotics or to 
intracameral cefuroxime [41]. Witkin et al. reported 
Hemorrhagic Occlusive Retinal Vasculitis (HORV) in 36 
eyes of 23 patients receiving intraocular vancomycin. 
Thirty-three of 36 eyes received intracameral bolus 
following cataract extraction, while one received 
intravitreal injection and two received vancomycin via an 
irrigation bottle. Visual prognoses were poor in the 
majority of cases. The authors suggest a type III 
hypersensitivity reaction, based on timing and clinical 
presentation of symptoms [42] [43]. Further insight in 
the pathophysiology of HORV, based on histologic 
specimen, revealed a predominately T-cell, non-
granulomatous inflammatory component, confined 
completely to the choroid, without evidence of 
leukocytoclastic vasculitis as had been previously 
theorized. Ultrasound biomicroscopy revealed severely 
ischemic iris and ciliary body, which was corroborated on 
the histologic specimen [44]. 
Intravitreal Ceftazidime 
Mechanism of Action and Pharmacokinetics 
Ceftazidime is a third-generation cephalosporin, which 
broadly covers gram-negative bacteria, including 
Pseudomonas aeruginosa. Ceftazidime is bactericidal and 
lyses bacteria by cross-linking of the cell wall via a 
transpeptidase reaction. The half-life of ceftazidime in 
phakic rabbit eyes is 13.8 hours [45]. When combined 
with vancomycin, ceftazidime forms a precipitate in 
solution, likely secondary to the alkalinity of vancomycin 
and the acidity of ceftazidime. Therefore, it is 
recommended to inject the two antibiotics, separately. 
Alternatively, a small air bubble can be aspirated in 
between the two medications, if one prefers fewer 
injections in the eye. 
Spectrum of Activity and Resistance 
Ceftazidime has a broad therapeutic index and high in-
vitro antimicrobial activity, administered at a dose of 
2.25 mg/0.1 mL [46, 47]. Irvine et al. found that gram-
negative endophthalmitis isolates had sensitivities of 
100% to ceftazidime and 97% to amikacin [48]. A review 
corroborated these results, showing higher sensitivities 
to ceftazidime compared to aminoglycoside in isolates 
with gram-negative endophthalmitis [49]. It is possible 
that bacterial resistance to ceftazidime could vary from 
one geographical region to another, as several studies 
originating from India reported high rates of resistance in 
gram-negative organisms, ranging from 18% to 49% [50, 
51].
 
Adverse Effects 
Use of intravitreal ceftazidime appears safe and has not 
been associated with signs of retinal toxicity for doses up 
to 10mg/0.1 mL in primates [52]. 
Intravitreal Amikacin and Gentamicin 
Mechanism of Action and Pharmacokinetics  
The aminoglycosides, gentamicin, and amikacin, are 
bacteriostatic and disrupt cell replication by binding to 
the 16S ribosomal RNA within the 30S ribosomal subunit, 
and halts genetic production. This subsequently leads to 
the interruption of bacterial protein synthesis [53].  
Spectrum of Activity and Resistance 
Aminoglycosides protect mainly against gram-negative 
bacteria and may also have some advantages over other 
gram-negative antibiotics (e.g. ceftazidime). 
Aminoglycosides are not dependent on the inoculum size 
and can exhibits synergy with vancomycin against gram 
positive cocci. However, data from clinical studies 
showed no significant differences in visual outcomes, in 
treatment with ceftazidime versus amikacin, including 
eyes with bacterial endophthalmitis [53]. There are 
increasing numbers of resistant bacterial strains to 
aminoglycosides, such as those forming aminoglycoside-
modifying enzymes that result in poor drug binding to 
ribosomes [54]. Intravitreal amikacin, which is more 
commonly used than gentamicin, is dosed at 0.4 mg/0.1 
mL and has a vitreous half-life of 25.5 hours in phakic, 
uninflamed rabbit eyes [20]. 
Adverse Effects 
Aminoglycoside toxicity is well-documented in the 
literature. Retina and retinal pigmented epithelium are 
damaged at doses close to therapeutic levels, which is 
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thought to be, in part, due to retinal ischemia [55]. Some 
drugs in the aminoglycoside family seem to have a more 
profound toxicity on ocular tissues. Gentamicin has been 
found to have greater retinal toxicity than amikacin in 
rabbit eyes [56, 57]. Notably, aminoglycoside-induced 
retinal infarction is uncommon with one out of 420 eyes 
reported in the EVS, after treatment with intravitreal 
amikacin [33]. 
Intravitreal Moxifloxacin 
Mechanism of Action and Pharmacokinetics 
Moxifloxacin interacts with topoisomerase II (DNA 
gyrase) and topoisomerase IV to interfere with bacterial 
DNA synthesis [58]. 
Spectrum of Activity and Resistance 
The spectrum of quinolones has advantageous activity 
against gram-positive and gram-negative bacteria. Fourth 
generation quinolones, such as moxifloxacin and 
levofloxacin, have extended gram-positive activity, in 
comparison to earlier generations of quinolones. 
However, ciprofloxacin, a second generation quinolone, 
has better coverage against pseudomonas species [4, 59-
61]. When compared to vancomycin, the efficacy of 
intravitreal moxifloxacin has demonstrated similar 
histopathological, bacteriological, and clinical outcomes 
in animal studies comparing treatment of Staphylococcus 
aureus endophthalmitis [62]. Resistance to this drug is, 
however, increasing; the most commonly noted are 
methicillin-sensitive Staphylococcus epidermidis isolates 
[63]. A study examining 327 isolated gram-positive 
organisms in patients with endophthalmitis found isolate 
sensitivities of 47% to moxifloxacin versus 100% to 
vancomycin [64]. The current recommended dose is 500 
μg/0.1 mL in order to achieve a vitreous concentration of 
approximately 125 μg/0.1 mL [65]. Along with increasing 
resistance, the limited vitreous half-life of moxifloxacin is 
also of concern. Lyer et al. showed that intravitreal 
moxifloxacin has a 1.72-hour half-life, and is only 
eliminated from the vitreous through both aqueous and 
posterior route. Nevertheless, vitreous concentrations 
surpassed the MIC of 90% of common endophthalmitis-
causing organisms (MIC90) by one to several orders of 
magnitude, after 12 hours, when investigated in 
uninflamed phakic rabbit eyes [66]. 
Adverse Effects 
Though clinical studies are limited, intravitreal use of 
moxifloxacin is considered safe [62, 67]. In addition, 
electrophysiological studies performed on rabbit eyes 
and as part of in vitro studies of human RPE cells 
demonstrated that concentrations of up to 150 μg/mL do 
not cause retinal damage [68, 69]. However, adverse 
effects have been observed with intracameral use of 
moxifloxacin, following ocular surgery. A recent meta-
analysis showed increased central corneal thickness and 
macular thickening as possible side adverse effects, 
although, many of the studies found no significant 
changes in the cornea or macula following intracameral 
use of moxifloxacin [70]. 
In summary, empirical broad spectrum intravitreal 
antibiotics remains the standard treatment for bacterial 
endophthalmitis. Intravitreal vancomycin is the 
consensus intravitreal anti-infective choice to treat gram-
positive endophthalmitis, despite some evidence of 
emerging vancomycin-resistant bacteria in 11% of 
culture-proven isolates [71]. While in the EVS, [33] 
intravitreal vancomycin and amikacin was injected in all 
eyes, contemporary data indicates increased preference 
for the use of a third-generation cephalosporin, in 
particular ceftazidime over amikacin for gram-negative 
coverage because of concerns of aminoglycoside-related 
toxicity [72] [73]. 
Antifungal Therapy 
Rationale for Treatment 
Fungal endophthalmitis is commonly encountered as a 
complication of systemic fungal infection, yet
 
can also 
occur following intraocular surgery or penetrating 
trauma [74-76]. The most common fungal pathogens, 
include Aspergillus spp. and Candida spp. Emergence of 
Fusarium spp. and Scedosporium spp. has been reported 
more recently. Intraocular fungal infection is primarily a 
foci of hematogenous spread from systemic infection; 
therefore, systemic antifungal therapy is usually required 
with a preference for fluconazole and voriconazole, given 
their ability to achieve high drug concentration in the 
vitreous and ocular tissues [74-76]. In general, flat lesions 
involving the choroid/outer retina can only be managed 
with systemic treatment because of the rich blood supply 
of the choroid, while lesions extending to the inner retina 
and the vitreous are usually treated with a combination 
of systemic antifungal therapy and intravitreal injections 
[74-76]. Vitrectomy is a commonly used modality in 
treatment of fungal endophthalmitis. However, the role 
and the ideal timing of vitrectomy in a course of fungal 
endophthalmitis is unclear. According to a retrospective 
study of 44 eyes with endogenous Candida 
endophthalmitis by Sallam et al., early PPV, within one 
week of presentation, did not significantly reduce the risk 
of profound visual loss (postoperative Snellen acuity of 
≤20/200), yet it decreased the risk of retinal detachment 
by five folds [74]. A recent large retrospective cohort 
showed immediate vitrectomy, performed at the time of 
initial injection of antimicrobial agents, to be associated 
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with significant visual acuity improvement (mean 
logarithm of the minimum angle of resolution (logMAR) 
2.534 to 2.153, p=0.027) in eyes with culture-proven 
fungal endophthalmitis as compared to no significant 
visual acuity improvement (mean logMAR 2.336 to 2.367, 
P = 0.844) in eyes, where vitrectomy was deferred. 
However, there was no difference in the absolute 
postoperative visual acuity or the proportions of eyes 
reaching a postoperative acuity of 20/200 [77].  
Amphotericin B  
Mechanism of Action and Pharmacokinetics 
Although the use of intravitreal fluconazole in human 
eyes has previously been described, until recently, 
Amphotericin B (AMB), a polyene antifungal,  was the 
main intravitreal antifungal drug, routinely used in 
clinical settings [24].
 
Amphotericin B utilizes ergosterol 
on the cell membrane to form complex creating pores 
within the membrane and causes cell death. 
Amphotericin B has a relatively long half-life in the 
vitreous after intravitreal administration, ranging from 
6.9 to 15.1 days. The recommended intravitreal dose of 
AMB is in the range of 5 to 10 µg. There is no 
standardization of the number or time of repeat 
injections due to a variety of factors, aside from a four-
fold increase in elimination after vitrectomy. Subsequent 
injections depend on the clinical response of the eye 
after initial injection, amount of retinal-ocular 
compromise from inflammation, and states of the 
vitreous cavity [78].  
Spectrum of Activity and Resistance  
Amphotericin B has a wide spectrum of activity against 
several fungal species [75]. However, recent reports have 
revealed increased resistance of a few non-Candida 
albicans species [79]. Moreover, AMB resistance has 
been clinically observed with other fungi, such as 
Aspergillus spp. and Fusarium spp. [75]. 
Adverse Effects 
Reports have shown the risk of development of focal 
toxicity of the retina with doses as low as 1 µg [4]. 
Increased rates of vitreous inflammation and extensive 
retinal necrosis were also reported with higher 
intravitreal concentrations [80, 81].   
Voriconazole 
Mechanism of Action and Pharmacokinetics  
Voriconazole, a second-generation triazole, is a newer 
drug, reserved for the treatment of severe fungal 
infections. Similar to other triazoles, voriconazole inhibits 
14-α-demethylase, a cytochrome p-450 enzyme, thereby, 
interfering with ergosterol synthesis, which results in 
lysis of the fungal cells. Voriconazole showed good ocular 
bioavailability when used systemically (oral or 
intravenous), achieving therapeutic levels in both the 
vitreous and the aqueous humor [82]. Pharmacokinetic 
studies of intravitreal voriconazole demonstrated that 
drug levels achieved during the first eight hours are at 
least 10 folds greater than the MIC of most fungal 
organisms, causing endophthalmitis. However, because 
its half-life in the vitreous is as short as 2.5 hours and 
drug concentration exhibits early exponential decay, 
repeat intravitreal treatment to maintain a therapeutic 
level is usually required [83]. 
Spectrum of Activity and Resistance 
Voriconazole has an extremely effective spectrum of 
activity against yeasts and molds. It was shown to be 
efficacious when used for Aspergillus spp., Blastomyces 
dermatitidis, Candida spp., Coccidioides immitis, 
Cryptococcus neoformans, and Histoplasma capsulatum 
[84]. A recent retrospective study of 47 fungal isolates 
from yeast and mold infection in eyes with fungal 
endophthalmitis, reported 100% susceptibility of the 
isolates to intravitreal voriconazole, as compared to only 
69% to intravitreal AMB [75]. 
Adverse Effects 
Intravitreal voriconazole has been shown to be 
associated with a lower risk of retinal toxicity when 
compared to animal models utilizing intravitreal AMB. In 
rat retinas, no histopathological or electroretinographic 
changes were seen, even with concentrations of up to 25 
µg/mL [85]. Focal areas of necrosis, however, did occur 
with concentrations of 50 µg/mL or more. This has led to 
extrapolation that up to 100 µg of intravitreal 
voriconazole could be safely used in human eyes. 
Clinically, such intravitreal voriconazole dosing has not 
shown evidence of toxicity to the retina [86]. However, 
the acquisition cost of voriconazole is much higher than 
that of AMB, which may limit its usefulness in some 
countries.   
Caspofungin 
Mechanism of Action and Pharmacokinetics 
Caspofungin noncompetitively inhibits β(1,)-D-glucan 
synthase, which is an enzyme responsible for cell wall 
formation. Caspofungin has a particularly low oral 
bioavailability, measuring less than 0.2%, yet, 
intravenously, has a much higher distribution in most 
tissues. An exception is in the eye due to its large 
molecular mass (1,213 Dalton). In vitro, the MIC of 
caspofungin has been measured at 0.03 to 1 µg/mL and 
0.06 µg/mL for Candida and Aspergillus spp., 
respectively. In rabbit eyes, mean vitreous concentration 
was 6.06±1.76 µg/mL after caspofungin injection, which 
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was well-above the MIC. However, like voriconazole, 
concentrations rapidly decreased due to exponential 
decay, despite having a longer half-life of 6.28 hours [87]. 
Spectrum of Activity and Resistance 
Caspofungin has a narrower spectrum of coverage when 
compared to voriconazole [84]. However, the MIC for 
Candida and Aspergillus species is much higher with 
voriconazole than caspofungin. A recent case report 
showed resolution of endophthalmitis in patients with 
AMB- , fluconazole-, and voriconazole-resistant Candida 
ciferrii [88]. However, in a 15-year review of culture-
proven fungal endophthalmitis, isolates showed 
sensitivities of 70% with caspofungin compared to 93% 
with voriconazole [89]. 
Adverse Effects 
Caspofungin has an excellent safety profile when injected 
into the intravitreal space in animal models with one 
study showing normal ERGs after injection of 10 to 200 
µL of caspofungin into rabbit eyes [87]. Although not 
readily employed, caspofungin may be a viable option in 
intravitreal treatment of fungal endophthalmitis due to 
its favourable safety profile [84].  
In summary, intravitreal voriconazole is currently the 
intravitreal treatment of choice of fungal 
endophthalmitis particularly if infection with mold 
species cannot be excluded. Intravitreal AMB remains a 
reasonable alternative in eyes with fungal 
endophthalmitis due to yeast when voriconazole use is 
not feasible. 
Antiviral Therapy 
Rationale for Treatment 
Cytomegalovirus (CMV) is a common cause of infectious 
retinitis. It is the most common cause in defective T-cell-
mediated immunity conditions, such as AIDS, lympho-
reticular and malignancies, and in patients on long-term 
immunosuppressive medications. Retinitis due to CMV 
has also been reported following intraocular 
immunosuppressive therapy in immunocompetent 
patients [90-92]. 
Current treatment recommendation for CMV retinitis in 
patients with HIV is mainly dependent on systemic 
therapy. It has shown to be associated with increased 
survival and decreased viral dissemination to the fellow 
eye.  Studies performed in the post-Highly Active 
Antiretroviral Therapy (HAART) also demonstrated 
superiority of systemic antiviral treatment to repeat 
intravitreal injections in controlling the retinitis, though 
in earlier studies, systemic treatment was found to be 
inferior to sustained release ganciclovir implant in this 
regard [93]. Intravitreal antiviral therapy is, therefore, 
mainly used as an adjunctive treatment for CMV retinitis 
in patients with HIV, who cannot tolerate or have 
resistance to systemic therapy. It is also used to 
supplement systemic therapy in patients with zone 1 
disease. There is a paucity of literature on treatment of 
CMV retinitis in patients without HIV. Recent evidence 
suggests a possible role for intravitreal antiviral injections 
not only as an adjunctive to systemic anti-CMV therapy, 
yet also as an alternative treatment in patients, who are 
iatrogenically immunosuppressed and in whom cessation 
of immunosuppressive therapy has resulted in immune 
recovery. In these non-HIV immunosuppressed patients, 
53.84% of eyes had complete resolution of retinal lesions 
within one month of ganciclovir injections [94]. 
A separate entity that causes acute necrotizing retinitis is 
Acute Retinal Necrosis (ARN). Its most common causative 
etiologies are Herpes Simplex Virus (HSV) or Varicella 
Zoster Virus (VZV). Few controlled trials have been 
conducted for the treatment of ARN; therefore, 
anecdotal evidence primarily guides treatment. Systemic 
treatment comprised of intravenous acyclovir or oral 
valacyclovir is the mainstay of treatment for ARN, 
particularly to provide protection for the fellow eye. Still, 
intravitreal therapy plays a key role as an adjunctive 
measure and may decrease the risk of retinal 
detachment. In one study, Wong et al. showed a 
reduction in the risk of retinal detachment by 40% 
(53.6% versus 75.0%) when intravitreal foscarnet was 
added to systemic treatment in VZV retinits [95]. 
Progressive Outer Retinal Necrosis (PORN) syndrome is 
another form of necrotizing retinitis, caused by VZV that 
occurs in severely immunocompromised patients and 
often results in profound loss of vision. Though 
treatment outcomes in PORN are generally dire, with 
retinal detachment reported in 51% of eyes and nearly 
20% with progression to no light perception, visual 
results obtained with combination treatment using 
systemic and local antiviral therapy appears to be 
superior to systemic therapy alone  [96]. 
Intravitreal Ganciclovir 
Mechanism of Action and Pharmacokinetics  
Ganciclovir is a guanosine analogue that selectively 
inhibits DNA polymerase in CMV cells after being 
activated in vivo by viral and cellular kinases. Data from 
human eyes treated with intravitreal ganciclovir 
demonstrated a mean half-life of 18.8 hours after 
administration with a concentration that remains above 
the level that is sufficient to inhibit  50% of CMV virus 
activity (ID50) for up to seven days [97]. 
Spectrum of Activity and Resistance 
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Ganciclovir is mainly employed in treating CMV retinitis 
yet has also been used for treatment of VZV retinitis [96]. 
An induction dose of 2 mg/0.1 mL of ganciclovir is given 
intravitreally bi-weekly for two to three weeks, followed 
by weekly injections for maintenance therapy. Dosages 
of ganciclovir 3 mg can be given more frequently in 
combination with intravitreal foscarnet in patients, who 
cannot tolerate systemic therapy [98, 99]. 
Adverse Effects 
Intravitreal ganciclovir use is generally tolerated without 
associated decreased visual acuity or ocular toxicity. Even 
with higher doses of 3 mg, definite signs of retinal 
toxicity were identified in clinical scenarios; however, 
histological evidence of mild iris atrophy has been 
demonstrated [98]. 
Ganciclovir Implant 
Ganciclovir implant releases ganciclovir at a steady state 
over six months. This device requires surgery to secure it 
intraocularly to the sclera at the region of the pars plana. 
The ganciclovir implant  has demonstrated superiority 
over systemic CMV treatment in controlling retinitis 
progression [93]. Though ganciclovir implant surgery is 
associated with a low risk of serious postoperative 
complications, including retinal detachment and ocular 
hypotony, the risk of vitreous hemorrhage (10%) or 
endophthalmitis (0.46%) is substantially higher than 
those observed after intravitreal injections [100, 101]. 
Since the era of HAART therapy, the incidence of CMV 
retinitis has decreased in patients with HIV, and the 
usefulness of ganciclovir implant is limited. 
Intravitreal Foscarnet  
Mechanism of Action and Pharmacokinetics  
Foscarnet is an analog of pyrophosphate, designed to 
inhibit viral replication through binding to the DNA 
polymerase enzyme, preventing DNA chain elongation. In 
contrast to ganciclovir, foscarnet does not require 
further in vivo activation by viral or cellular enzymes. 
Lopez-Cortes et al. compared the pharmacokinetics of 
foscarnet and ganciclovir in a rabbit model. Their results 
demonstrated that although the half-life of the foscarnet 
in the vitreous is significantly prolonged (77 hours) than 
that of ganciclovir (8 hours), drug concentrations found  
in the retinal tissues were much lower than those for 
ganciclovir, and decreased more rapidly [102]. 
Spectrum of Activity and Resistance 
Foscarnet inhibits the replication of multiple herpes 
family viruses and hence could be used for treatment of 
retinitis due to CMV, HSV and HZV. This makes it 
particularly useful for treatment of ARN, thereby, 
providing good initial control of virus replication until 
vitreous Polymerase Chain Reaction (PCR) result is 
received and the specific virus is identified. The induction 
dosage of intravitreal foscarnet is 2.4 mg/0.1 mL once or 
twice weekly, followed by once weekly, for maintenance. 
Though treatment with foscarnet is effective, resistance 
may sometimes develop [103]. 
Adverse Effects 
Intravitreal foscarnet is tolerated well without report of 
associated decreased vision or clinical signs of retinal 
toxicity [98, 99]. 
Intravitreal Cidofovir 
Cidofivir is an antiviral, which inhibits viral DNA synthesis, 
selectively, thereby, suppressing replication of CMV 
[104].
 
Intravitreal cidofivir is a very effective treatment 
yet is not frequently used due to the exceeding incidence 
of ocular inflammation, resulting in uveitis and ocular 
hypotony [105].  
Anti-toxoplasma Therapy 
Rationale for Treatment 
Toxoplasma gondii, an obligate intracellular parasite, is 
the most common cause of posterior uveitis of infectious 
origin in immunocompetent individuals [106]. 
Toxoplasma-induced retinochoroiditis is often self-
limiting and there is no level I evidence to indicate a 
substantial benefit of routine antimicrobial treatment in 
immunocompetent patients. Treatment is usually 
reserved for active lesions associated with severe vitritis 
or located in the macula or near the optic nerve [77].  
Systemic therapy is the current treatment of choice for 
ocular histoplasmosis. The aim of drug therapy in 
treating toxoplasmosis is to decrease the parasitic load 
without increasing the amount of ocular inflammation. 
The best treatment medication or regimen is yet to be 
established, and there are currently more than 20 
regimens with at least nine medications commonly used, 
including sulfadiazine, pyrimethamine as well as 
clindamycin or trimethoprim/sulfamethoxazole [107]. 
Because of the potentially serious systemic adverse 
effects that could be associated with anti-toxoplasma 
medications and the fact that toxoplasma reactivation is 
commonly unilateral in immunocompetent patients, 
there has been recent interest in treating toxoplasma 
retinitis, solely by intravitreal therapy, instead of 
systemic medications [108-110]. 
Intravitreal Clindamycin 
Clindamycin is an antibacterial that interferes with 
protein synthesis by binding to the 50s ribosomal subunit 
in bacterial cells. In both human and animal eyes, ocular 
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toxoplasmosis has been successfully treated with 
clindamycin. Clindamycin has also demonstrated some 
effects against cystic toxoplasmosis,
 
decreasing the tissue 
load of the toxoplasma cysts [108].  
In two single-masked, clinical trials that comprised of 134 
patients with active ocular toxoplasmosis randomized to 
treatment with either intravitreal clindamycin plus 
dexamethasone or to systemic therapy with 
pyrimethamine, sulfadiazine, folic acid and prednisolone, 
intravitreal clindamycin exhibited benefits in the 
treatment of Toxoplasma retinochoroiditis [108, 111]. 
After six weeks, no difference was noted in visual acuity, 
vitreous inflammatory response or lesion size reduction. 
The rate of retinitis recurrence in two years was 
comparable between eyes treated with systemic and 
intravitreal therapy. Major complications secondary to 
intravitreal injection were not encountered aside from 
adverse drug reactions in three patients in the systemic 
treatment arm. In eyes treated with intravitreal therapy, 
the mean number of injections was approximately 1.6 in 
six weeks [108]. 
Adverse Events 
Intraocular clindamycin has not demonstrated retinal 
toxicity in various studies and seems to be generally well 
tolerated in regards to side effect profile [108-110]. 
Administration through the intravitreal route avoids 
some side effects from systemic therapy, such as toxic 
megacolon and pseudomembranous colitis, yet it does 
not avoid the problem of drug sensitivity [112]. 
Intravitreal Injection of 
Trimethoprim/Sulfamethoxazole 
Trimethoprim/Sulfamethoxazole (co-trimoxazole) 1.28 
mg/0.08 mL has recently been suggested as an 
alternative treatment for intravitreal clindamycin for 
treatment of retinitis associated with toxoplasmosis. Co-
trimoxazole, is a combination of two antimicrobial 
agents, trimethoprim and sulfamethoxazole, that act by 
inhibiting two successive steps of the de novo synthesis 
of tetrahydrofolate, the biologically active form of folic 
acid inside the organism. As each drug component of co-
trimoxazole works on a different step of the folic acid 
cycle, a synergistic response against toxoplasmosis is 
achieved, and resistance is likely to develop more slowly 
than if each drug is administered alone. Soheilian et al. 
showed that clotrimazole treatment resulted in 
resolution of all four cases in a case series using weekly 
or biweekly injection, without the need for systemic 
treatment [113]. More recently, intravitreal injection of 
co-trimoxazole combined with dexamethasone was used 
to treat recurrent toxoplasmosis retinitis in a prospective 
study of 13 patients and 13 eyes. Mean baseline Snellen 
visual acuity was 20/400 and improved to 20/63 on 
average, eight weeks after a single injection [114]. 
Adverse Events 
There is only scarce literature on the safety of intravitreal 
co-trimoxazole in humans. However, in rabbit eyes, co-
trimoxazole caused no clinical, electrophysiological or 
histological abnormalities when evaluated in one study 
[115]. In a small prospective cohort, patients treated with 
co-trimoxazole and dexamethasone were not shown to 
have any adverse effects [114]. 
Future Direction 
Numerous innovative drug delivery products are now in 
developments with the aim of providing targeted 
treatment to the posterior segment while limiting the 
difficulties associated with frequent intravitreal 
injections. Of the delivery products currently under 
investigation, ones that could be used in treatment of 
intraocular infection in the future are long acting 
antimicrobial implants that can be injected in the 
outpatient setting and refillable surgical implants [116]. 
Delivery of antimicrobials through the sclera, using low-
level electric current iontopheresis, could also be a 
promising and low-risk route for drug administrations in 
the future [117]. Additionally, there has been a recent 
interest in nano-carriers, which may be of benefit in 
treatment of intraocular infection. These nanoparticles 
deliver drugs to specific portions of the posterior 
segment. Nanoparticles also improve passage of larger, 
poorly water-soluble or unstable molecules and increase 
the time of contact between the intraocular drug and 
target tissues of the posterior segment [118]. Phase II 
studies have investigated the suprachoroidal space as a 
potential treatment modality for retinal vein occlusion 
and non-infectious uveitis [119, 120]. Utilizing 
triamcinolone in the SCS via a novel microneedle to treat 
posterior uveitis has garnered some success with good 
safety profile [119]. No studies have used this approach 
in treatment of endophthalmitis or other infectious 
causes to date. 
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Table 1: Important Characteristics of Commonly used Intravitreal Antimicrobial Drugs 
Drug Target site; mechanism of action Recommended 
Dose 
Vitreous half-
life, in hours 
(model  eye) 
Spectrum of activity Time for re-
treatment if 
needed (hours) 
Antibacterials      
Vancomycin2, 120 Cell wall; prevents polymerization 
of peptidoglycan 
1.0-2.0mg/ 
0.1mL 
25-56 (rabbit) Gram-positive bacteria 36-72 
Ceftazidime134 Cell wall; inhibits the transpeptidase 
reaction 
2.25mg/0.1mL 13.8 (rabbit) Gram-negative bacteria 
including Pseudomonas 
aeruginosa 
48-72 
Amikacin103,129 Protein synthesis; binds to the 30s 
ribosomal subunit of bacteria 
0.4mg/0.1mL 22.5 (rabbit) Gram-positive cocci & 
gram-negative bacteria 
36-60 
Gentamycin103 Protein synthesis; binds to the 30s 
ribosomal subunit of bacteria 
0.1mg/0.1mL NA Gram-positive cocci & 
gram-negative bacteria 
NA 
Moxifloxacin79,84 DNA: interferes with DNA gyrase 
and topisomerase IV enzymes 
0.5mg/0.1mL 1.72 (rabbit) Gram-positive & gram-
negative bacteria 
12 
Antifungals      
Amphotericin B32,140,157 Cell membrane; complexes with  
cell membrane ergosterol resulting 
in disturbed cell membrane function 
0.05mg/0.1mL 25.5-56 
(human) 
Most yeasts & moulds 48 
Voriconazole23,71,107,139,140 Cell membrane; interferes with 
ergosterol synthesis resulting in 
disturbed cell membrane function 
0.1mg/0.1mL 2.5-6.5 (human) Extended antifungal 
spectrum 
24-48 
Antivirals      
Ganciclovir17,113,154 DNA; selectively inhibits DNA 
polymerase in viral cells preventing 
DNA chain elongation 
2mg/0.05mL 18.8 (human) CMV. Also HSV & VZV 72* 
Foscarnet120,150 DNA; inhibits DNA polymerase 
enzyme preventing DNA chain 
elongation 
2.4mg/0.1mL 77 (rabbit) HSV, VZV & CMV 72* 
Antiprotozoals      
Clindamycin10,126,144 Protein synthesis; binds to the 50s 
ribosomal subunit of organism 
1mg/0.1mL 40 (human) Toxoplasma gondii. Also 
gram-positive cocci & 
anerobs 
72 
Trimethoprim/sulfa-
methoxazole 35 
Metabolic pathways; inhibits the 
bacterial synthesis of 
tetrahydrofolic acid 
1.28 mg/0.08 
mL 
NA Toxoplasma gondii.  Also 
gram-positive & negative 
bacteria 
72 
mg/ml: milligrams per milliliters; NA: not available; CMV: Cytomegalovirus; HSV: Herpes Simplex Virus; VZV: Varicella Zoster Virus. 
* Treatment is used every 72 hours during the induction phase for about 2-3 weeks followed by weekly maintenance treatment.  
 
CONCLUSION 
Using the intravitreal route to administer antimicrobial 
drugs has been the standard approach for treatment of 
postoperative bacterial endophthalmitis, yet treatment 
of endogenous endophthalmitis, whether viral, fungal or 
bacterial, requires a multi-modality approach with 
intravitreal therapy being mainly used as an adjunctive to 
systemic antimicrobial treatment. While there has been 
recent interest in treating toxoplasma retinitis solely by 
intravitreal therapy instead of systemic antibiotics, there 
is still not enough evidence to support this approach for 
all patients. Table 1 outlines the important characteristics 
of commonly used intravitreal antimicrobial drugs, 
including mechanism of action, dosing, and half-life in 
the vitreous and spectrum of activity. 
Intravitreal administration of antimicrobial drugs 
represents an important strategy in the armamentarium 
for the treatment of infectious posterior uveitis. As the 
intravitreal route bypasses the blood ocular barriers, this 
route of administration allows rapid and direct drug 
delivery to the vitreous cavity at very high concentrations 
that exceeds the MIC of most organisms, while 
decreasing systemic sequelae. This is of utmost 
importance in eyes that are at imminent risk of 
developing severe visual loss due to macular or optic 
nerve involvement and in patients, who cannot tolerate 
systemic medications [13]. However, intraocular therapy 
can be associated with ocular toxicity, as the difference 
between the therapeutic and the toxic doses of some 
antimicrobial drugs falls within a narrow concentration 
range. 
Method of Literature Search 
This review was based mainly on recent literature during 
the last ten years with inclusion of some relevant older 
articles, particularly those related to drug 
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pharmacokinetics. In addition, case reports of a 
particular relevance were also reviewed. MEDLINE 
database search was conducted using the following key 
words alone and in various combinations: amikacin, 
amphotericin, caspofungin, ceftazidime, cefuroxime, 
choroiditis, cidofovir, ciprofloxacin, clindamycin, 
endophthalmitis, foscarnet, ganciclovir, gentamycin, 
herpes, intracameral, intraocular, intravitreal, 
moxifloxacin, pharmacodynamics, pharmacokinetics, 
quinolones, retinitis, suprachoroidal space, toxoplasma, 
traumatic, vancomycin, and voriconazole. Relevant 
articles only in English language were obtained and 
reviewed. The electronic database search engine was last 
searched in August 2018. 
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